IMMUNOTHERAPY AS NOVEL TREATMENT OF LUNG CANCER: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.22159/ajpcr.2022.v15i12.46133Keywords:
Lung cancer, Immunotherapy, Immune checkpoint inhibitors, Non-SCLC, Antigen-specific cancer vaccines, c-MET oncogeneAbstract
Lung cancer is the top cause of cancer-related fatalities in both men and women around the world, and the second most commonly diagnosed cancer in both men and women. For many patients, traditional chemotherapy (CT) fails to give long-term benefit. Moreover, newer medicines targeting activating mutations in EGFR or ALK have shown increased response rates over CT in the minority of patients with these mutations; however, the majority of patients do not have actionable mutations and will not benefit from targeted therapies. In addition, several combinations of chemotherapeutic medicines with the angiogenesis inhibitor bevacizumab have provided only minor additional benefits. However, immunotherapy using checkpoint inhibitors has shown to have a lot of potential in the treatment of advanced non-SCLC (NSCLC) in recent trials. These new medications encourage the host immune system to recognize tumor cells as foreign invaders and halting their growth. They help alleviate immune system suppression, which allows tumor development to be tolerated. In checkpoint immunotherapy, humanized monoclonal antibodies targeting checkpoint signals such as programmed cell death receptor (PD-1) and programmed cell death ligand are employed (PD-L1). The immune system can be triggered to fight the tumor by inhibiting these receptors and signals. Immunotherapy for advanced lung cancer has created a new paradigm of therapeutic options, with increased survival and response rates and a less severe but distinct side profile when compared to CT. The PD-1 inhibitors nivolumab and pembrolizumab, as well as the PD-L1 inhibitor atezolizumab, have been approved by regulatory authorities for the treatment of advanced NSCLC. Hence, the current review article focuses on the role of immunotherapy, newer agents used for checkpoint inhibitors in lung cancer, their epidemiology, risk factors, side-effect profiles, therapeutic indications, and their mechanism of action for the successful treatment of lung cancer.
Downloads
References
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006. doi: 10.1001/jama.2014.3741, PMID 24846037
Nakano T, Shimizu K, Kawashima O, Kamiyoshihara M, Kakegawa S, Sugano M, et al. Establishment of a human lung cancer cell line with high metastatic potential to multiple organs: Gene expression associated with metastatic potential in human lung cancer. Oncol Rep 2012;28:1727- 35. doi: 10.3892/or.2012.1972, PMID 22922681
Sharma P, Mehta M, Dhanjal DS, Kaur S, Gupta G, Singh H, et al. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem Biol Interact 2019;309:108720. doi: 10.1016/j. cbi.2019.06.033, PMID 31226287
Yu S, Wang R, Tang H, Wang L, Zhang Z, Yang S, et al. Evolution of lung cancer in the context of immunotherapy. Clin Med Insights Oncol 2020;14:1179554920979697. doi: 10.1177/1179554920979697, PMID 33447125
Khaltaev N, Axelrod S. Global lung cancer mortality trends and lifestyle modifications: Preliminary analysis. Chin Med J (Engl) 2020;133:1526- 32. doi: 10.1097/CM9.0000000000000918, PMID 32568874
Pavan A, Attili I, Pasello G, Guarneri V, Conte PF, Bonanno L. Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges. J Immunother Cancer 2019;7:205. doi: 10.1186/ s40425-019-0690-1, PMID 31383005
Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 2010;5:305-13. doi: 10.1097/ JTO.0b013e3181ce3d1d, PMID 20107422
Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 2013;5 Suppl 4:S389-96. doi: 10.3978/j. issn.2072-1439.2013.07.10, PMID 24102012
Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. Respirology 2016;21:821-33. doi: 10.1111/resp.12789, PMID 27101251
Jaggi P. A review article on lung cancer diagnosis and treatment. Res Rev J Med Health Sci 2017;6:1-9.
Visconti R, Morra F, Guggino G, Celetti A. The between now and then of lung cancer chemotherapy and immunotherapy. Int J Mol Sci 2017;18:1374. doi: 10.3390/ijms18071374, PMID 28653990
Sun J, Zhang Z, Bao S, Yan C, Hou P, Wu N, et al. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer. J Immunother Cancer 2020;8:e000110. doi: 10.1136/jitc- 2019-000110, PMID 32041817
Hopkins AM, Wagner J, Kichenadasse G, Modi N, Rowland A, Sorich MJ. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy. Int J Cancer 2020;147:3085-9. doi: 10.1002/ ijc.33133, PMID 32492185
Sanmamed MF, Nie X, Desai SS, Villaroel-Espindola F, Badri T, Zhao D, et al. A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer Immunotherapy. Cancer Discov 2021;11:1700-15. doi: 10.1158/2159-8290.CD-20-0962, PMID 33658301
Esposito G, Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, et al. Immunotherapy in small cell lung cancer. Cancers (Basel) 2020;12:2522. doi: 10.3390/cancers12092522, PMID 32899891
Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)- Novel approaches and future outlook. Mol Cancer 2020;19:141. doi: 10.1186/s12943-020-01260-z, PMID 32917214
Nasser NJ, Gorenberg M, Agbarya A. First line immunotherapy for non-small cell lung cancer. Pharmaceuticals (Basel) 2020;13:373. doi: 10.3390/ph13110373, PMID 33171686
Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: A randomized phase I/II trial. J Immunother Cancer 2020;8:e001001. doi: 10.1136/jitc-2020-001001, PMID 33051340
Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol 2019;12:63. doi: 10.1186/s13045-019-0759-9, PMID 31227004
Rehman S, Dy GK. MET inhibition in non-small cell lung cancer. E M J Respir 2018; 6:100-11.
He B, Dong D, She Y, Zhou C, Fang M, Zhu Y, et al. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. J Immunother Cancer 2020;8:e000550. doi: 10.1136/jitc-2020-000550, PMID 32636239
Wang F, Wang S, Zhou Q. The resistance mechanisms of lung cancer immunotherapy. Front Oncol 2020;10:568059. doi: 10.3389/ fonc.2020.568059, PMID 33194652
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. doi: 10.3322/caac.21660, PMID 33538338
Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44. doi: 10.1016/j.ccm.2011.09.001, PMID 22054876
Schabath MB, Cress D, Muñoz-Antonia T. Racial and ethnic differences in the epidemiology and genomics of lung cancer. Cancer Control 2016;23:338-46. doi: 10.1177/107327481602300405, PMID 27842323
Saha SP, Bhalla DK, Whayne TF Jr., Gairola CG. Cigarette smoke and adverse health effects: An overview of research trends and future needs. Int J Angiol 2007;16:77-83. doi: 10.1055/s-0031-1278254, PMID 22477297
Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res 2015;4:327-38. doi: 10.3978/j.issn.2218-6751.2015.08.04, PMID 26380174
Schneiderman N, Ironson G, Siegel SD. Stress and health: Psychological, behavioral, and biological determinants. Annu Rev Clin Psychol 2005;1:607-28. doi: 10.1146/annurev.clinpsy.1.102803.144141, PMID 17716101
Quinn GP, Sanchez JA, Sutton SK, Vadaparampil ST, Nguyen GT, Green BL, et al. Cancer and lesbian, gay, bisexual, transgender/ transsexual, and queer/questioning (LGBTQ) populations. CA Cancer J Clin 2015;65:384-400. doi: 10.3322/caac.21288, PMID 26186412
Benjamin R. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. Centers for Disease Control and Prevention (CDCP). 2010;978. ISBN-13: 978-0-16-084078-4.
Hecht SS. Tobacco smoke carcinogens and lung cancer. Curr Cancer Res 2011;6:53-74.
Furrukh M. Tobacco smoking and lung cancer: Perception-changing facts. Sultan Qaboos Univ Med J 2013;13:345-58. doi: 10.12816/0003255, PMID 23984018
Stiborova M. Formation of covalent dna adducts by enzymatically activated carcinogens and drugs in vitro and their determination by 32P-postlabeling. J Vis Exp 2018;133:57177. doi: 10.3791/57177, PMID 29630053
Donaldson MS. Nutrition and cancer: A review of the evidence for an anti-cancer diet. Nutr J 2004;3:19. doi: 10.1186/1475-2891-3-19, PMID 15496224
Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: New molecular insights. Respiration 2011;81:265-84. doi: 10.1159/000324601, PMID 21430413
Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA, et al. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. CA Cancer J Clin 2020;70:460-79. doi: 10.3322/caac.21632, PMID 32964460
Jain V, Berman AT. Radiation pneumonitis: Old problem, new tricks. Cancers (Basel) 2018;10:222. doi: 10.3390/cancers10070222, PMID 29970850
Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e1S-29. doi: 10.1378/ chest.12-2345, PMID 23649439
Field RW, Withers BL. Occupational and environmental causes of lung cancer. Clin Chest Med 2012;33:681-703. doi: 10.1016/j. ccm.2012.07.001, PMID 23153609
Chakraborty S, Ganti AK, Marr A, Batra SK. Lung cancer in women: Role of estrogens. Expert Rev Respir Med 2010;4:509-18. doi: 10.1586/ ers.10.50, PMID 20658912
Hsia CC, Hyde DM, Weibel ER. Lung structure and the intrinsic challenges of gas exchange. Compr Physiol 2016;6:827-95. doi: 10.1002/cphy.c150028, PMID 27065169
Charalampidis C, Youroukou A, Lazaridis G, Baka S, Mpoukovinas I, Karavasilis V, et al. Pleura space anatomy. J Thorac Dis 2015;7: S27-S-32. doi: 10.3978/j.issn.2072-1439.2015.01.48.
Mankekar G. Epidemiology, pathogenesis, and risk factors. In: Invasive Fungal Rhinosinusitis. Berlin: Springer; 2014. p. 7-14.
Kiyohara C, Takayama K, Nakanishi Y. Lung cancer risk and genetic polymorphisms in DNA repair pathways: A meta-analysis. J Nucleic Acids 2010;2010:701760. doi: 10.4061/2010/701760, PMID 20981350
Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG,et al. Non-small-cell lung cancer. Lancet 2011;378:1727-40. doi: 10.1016/S0140-6736(10)62101-0, PMID 21565398
Henschke CI, Yip R, Smith JP, Wolf AS, Flores RM, Liang M, et al. CT screening for lung cancer: Part-solid nodules in baseline and annual repeat rounds. AJR Am J Roentgenol 2016;207:1176-84. doi: 10.2214/ AJR.16.16043, PMID 27726410
Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999;118:1136-52. doi: 10.1016/S0022- 5223(99)70121-2, PMID 10595998
Brambilla E, Gazdar A. Pathogenesis of lung cancer signalling pathways: Roadmap for therapies. Eur Respir J 2009;33:1485-97. doi: 10.1183/09031936.00014009, PMID 19483050
Zheng M. Classification and pathology of lung cancer. Surg Oncol Clin N Am 2016;25:447-68. doi: 10.1016/j.soc.2016.02.003, PMID 27261908
Monaco SE, Rodriguez EF, Mahaffey AL, Dacic S. FGFR1 amplification in squamous cell carcinoma of the lung with correlation of primary and metastatic tumor status. Am J Clin Pathol 2016;145:55-61. doi: 10.1093/ajcp/aqv013, PMID 26712871
Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: Emerging differences in epidemiology, biology, and therapy. Chest 2005;128:370-81. doi: 10.1378/chest.128.1.370, PMID 16002959
Drilon A, Cappuzzo F, Ou SI, Camidge DR. Targeting MET in lung cancer: Will expectations finally be MET? J Thorac Oncol 2017;12:15-26. doi: 10.1016/j.jtho.2016.10.014, PMID 27794501
Zorzetto M, Ferrari S, Saracino L, Inghilleri S, Stella GM. MET genetic lesions in non-small-cell lung cancer: Pharmacological and clinical implications. Transl Lung Cancer Res 2012;1:194-207. doi: 10.3978/j. issn.2218-6751.2012.09.03, PMID 25806181
Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009;15:5714-23. doi: 10.1158/1078-0432.CCR-09-0070, PMID 19723643
Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, et al. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2014;89:284-99. doi: 10.1016/j.critrevonc.2013.11.006, PMID 24355409
Salgia R. MET in lung cancer: Biomarker selection based on scientific rationale. Mol Cancer Ther 2017;16:555-65. doi: 10.1158/1535-7163. MCT-16-0472, PMID 28373408
Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008;99:2280-5. doi: 10.1111/j.1349- 7006.2008.00916.x, PMID 19037978
Toschi L, Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010;6:239-47. doi: 10.2217/fon.09.164, PMID 20146583
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol 2020;20:651-68. doi: 10.1038/s41577-020-0306-5, PMID 32433532
Domingues D, Turner A, Silva MD, Marques DS, Mellidez JC, Wannesson L, et al. Immunotherapy and lung cancer: Current developments and novel targeted therapies. Immunotherapy 2014;6:1221-35. doi: 10.2217/imt.14.82, PMID 25496336
Yang L, Wang L, Zhang Y. Immunotherapy for lung cancer: Advances and prospects. Am J Clin Exp Immunol 2016;5:1-20. PMID 27168951
Murphy JF. Trends in cancer immunotherapy. Clin Med Insights Oncol 2010;4:67-80. doi: 10.4137/CMO.S4795
Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol 2008;3(6 Suppl 2):S164-70. doi: 10.1097/ JTO.0b013e318174e9a7, PMID 18520304
Somasundaram A, Burns TF. The next generation of immunotherapy: Keeping lung cancer in check. J Hematol Oncol 2017;10:87. doi: 10.1186/s13045-017-0456-5, PMID 28434399
Zhang S, Pease DF, Kulkarni AA, Kumar M, Shanley RM, Xu B, et al. Real-world outcomes and clinical predictors of immune checkpoint inhibitor monotherapy in advanced lung cancer. Clin Med Insights Oncol 2021;15:11795549211004489. doi: 10.1177/11795549211004489, PMID 34248362
Li R, Wang C, Liu L, Du C, Cao S, Yu J, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: A phase II clinical study. Cancer Immunol Immunother 2012;61:2125-33. doi: 10.1007/ s00262-012-1260-2, PMID 22581306
Khanna P, Blais N, Gaudreau PO, Corrales-Rodriguez L. Immunotherapy comes of age in lung cancer. Clin Lung Cancer 2017;18:13-22. doi: 10.1016/j.cllc.2016.06.006, PMID 27461776
Naylor EC, Desani JK, Chung PK. Targeted therapy and immunotherapy for lung cancer. Surg Oncol Clin N Am 2016;25:601-9. doi: 10.1016/j. soc.2016.02.011, PMID 27261918
Früh M, Peters S. Genomic features of response to combination immunotherapy in lung cancer. Cancer Cell 2018;33:791-3. doi: 10.1016/j.ccell.2018.04.005, PMID 29763618
Hendriks L, Besse B. New windows open for immunotherapy in lung cancer. Nature 2018;558:376-7.
Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, et al. Efficacy of docetaxel plus ramucirumab as palliative third-line therapy following second-line immune-checkpoint-inhibitor treatment in patients with non-small-cell lung cancer stage IV. Clin Med Insights Oncol 2020;14:1179554920951358. doi: 10.1177/1179554920951358, PMID 32884390
Declerck S, Vansteenkiste J. Immunotherapy for lung cancer: Ongoing clinical trials. Future Oncol 2014;10:91-105. doi: 10.2217/fon.13.166, PMID 24143916
Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev 2015;115:11109-46. doi: 10.1021/acs.chemrev.5b00109, PMID 26154342
Hall RD, Gray JE, Chiappori AA. Beyond the standard of care: A review of novel immunotherapy trials for the treatment of lung cancer. Cancer Control 2013;20:22-31. doi: 10.1177/107327481302000105, PMID 23302904
Tong W, Maira M, Roychoudhury R, Galan A, Brahimi F, Gilbert M, et al. Vaccination with tumor-ganglioside glycomimetics activates a selective immunity that affords cancer therapy. Cell Chem Biol 2019;26:1013-26.e4. doi: 10.1016/j.chembiol.2019.03.018, PMID 31105061
Saavedra D, Crombet T. CIMAvax-EGF: A new therapeutic vaccine for advanced non-small cell lung cancer patients. Front Immunol 2017;8:269. doi: 10.3389/fimmu.2017.00269, PMID 28348561
Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun 2019;10:5408. doi: 10.1038/ s41467-019-13368-y, PMID 31776331
Hirschowitz EA, Hiestand DM, Yannelli JR. Vaccines for lung cancer. J Thorac Oncol 2006;1:93-104. PMID 17409835
Slovin SF, Keding SJ, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 2005;83:418-28. doi: 10.1111/j.1440-1711.2005.01350.x, PMID 16033538
Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878- 87. doi: 10.1158/1078-0432.CCR-05-2013, PMID 16467102
Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol 2012;12:555-63. doi: 10.1097/ACI.0b013e328357ca53, PMID 22885888
Hirschowitz EA, Yannelli JR. Immunotherapy for lung cancer. Proc Am Thorac Soc 2009;6:224-32. doi: 10.1513/pats.200806-048LC, PMID 19349492
Aldarouish M, Wang C. Trends and advances in tumor immunology and lung cancer immunotherapy. J Exp Clin Cancer Res 2016;35:157. doi: 10.1186/s13046-016-0439-3, PMID 27686848
Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non-small cell lung cancer: Facts and hopes. Clin Cancer Res 2019;25:4592-602. doi: 10.1158/1078-0432. CCR-18-1538, PMID 30824587
Lim SM, Hong MH, Kim HR. Immunotherapy for non-small cell lung cancer: Current landscape and future perspectives. Immune Netw 2020;20:e10. doi: 10.4110/in.2020.20.e10, PMID 32158598
Published
How to Cite
Issue
Section
Copyright (c) 2022 CHOWDHURY MOBASWAR HOSSAIN, Subarnarekha Maitra, Nazmun Lyle, Meeta Gera, souvik Paul, Dishari Dutta
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
